Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) major shareholder Engine Capital Management, Lp acquired 13,061 shares of the company's stock in a transaction dated Wednesday, February 25th. The stock was acquired at an average price of $12.96 per share, for a total transaction of $169,270.56. Following the completion of the purchase, the insider directly owned 3,673,092 shares of the company's stock, valued at $47,603,272.32. This trade represents a 0.36% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
Engine Capital Management, Lp also recently made the following trade(s):
- On Tuesday, February 24th, Engine Capital Management, Lp bought 124,797 shares of Orthofix Medical stock. The shares were acquired at an average price of $12.55 per share, with a total value of $1,566,202.35.
Orthofix Medical Stock Performance
OFIX opened at $13.67 on Friday. The company has a quick ratio of 1.38, a current ratio of 2.45 and a debt-to-equity ratio of 0.39. The stock's 50 day moving average price is $14.12 and its two-hundred day moving average price is $14.70. The firm has a market capitalization of $541.17 million, a P/E ratio of -5.92 and a beta of 0.78. Orthofix Medical Inc. has a 12-month low of $10.24 and a 12-month high of $18.66.
Orthofix Medical (NASDAQ:OFIX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The medical device company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.44 by ($0.50). The business had revenue of $219.91 million during the quarter, compared to the consensus estimate of $218.72 million. Orthofix Medical had a negative net margin of 11.21% and a negative return on equity of 20.38%. On average, equities analysts forecast that Orthofix Medical Inc. will post -2.81 earnings per share for the current year.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on OFIX. Weiss Ratings restated a "sell (d-)" rating on shares of Orthofix Medical in a report on Thursday, January 22nd. Barrington Research lowered their price target on Orthofix Medical from $18.00 to $17.00 and set an "outperform" rating on the stock in a research note on Wednesday. TD Cowen began coverage on Orthofix Medical in a report on Tuesday, January 27th. They issued a "hold" rating and a $14.00 price target for the company. Finally, Canaccord Genuity Group reduced their price objective on Orthofix Medical from $24.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $18.25.
View Our Latest Analysis on OFIX
Orthofix Medical News Summary
Here are the key news stories impacting Orthofix Medical this week:
- Positive Sentiment: Engine Capital Management (a major shareholder) purchased a meaningful stake: 124,797 shares at ~$12.55 (~$1.57M) on Feb. 24 and an additional 13,061 shares at ~$12.96 on Feb. 25, raising its holdings and signaling confidence from a large investor. Engine Capital purchases OFIX shares
- Neutral Sentiment: Analysts trimmed targets but left constructive ratings: Canaccord cut its target from $24 to $20 (still a "buy") and Barrington trimmed $18→$17 ("outperform"); consensus remains mixed (average target ~$18.25). These cuts reduce upside expectations but maintain conviction among some analysts. Analyst notes and price-target changes
- Negative Sentiment: Quarterly earnings missed materially: OFIX reported $(0.06) EPS vs. $0.44 expected; revenue roughly in line but the EPS shortfall and negative margins/ROE pressured sentiment and sparked an intraday sell-off. Shares down after earnings miss
- Negative Sentiment: Management signaled margin delays and issued new 2026 guidance that shifts the narrative toward near-term execution risk, adding to downward pressure until margin recovery is clearer. Narrative shifting: margin delays and guidance
Hedge Funds Weigh In On Orthofix Medical
A number of hedge funds have recently modified their holdings of OFIX. Paradigm Capital Management Inc. NY boosted its stake in Orthofix Medical by 34.6% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 3,340,600 shares of the medical device company's stock valued at $37,248,000 after buying an additional 858,900 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Orthofix Medical by 86.6% during the third quarter. Millennium Management LLC now owns 1,475,718 shares of the medical device company's stock valued at $21,605,000 after acquiring an additional 684,850 shares during the period. Juniper Investment Company LLC boosted its stake in shares of Orthofix Medical by 23.3% in the 4th quarter. Juniper Investment Company LLC now owns 3,510,333 shares of the medical device company's stock valued at $53,217,000 after purchasing an additional 663,278 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Orthofix Medical by 659.5% in the 2nd quarter. Bank of America Corp DE now owns 687,410 shares of the medical device company's stock worth $7,665,000 after purchasing an additional 596,907 shares during the last quarter. Finally, Engine Capital Management LP increased its position in shares of Orthofix Medical by 13.6% during the 2nd quarter. Engine Capital Management LP now owns 4,251,671 shares of the medical device company's stock worth $47,406,000 after purchasing an additional 510,281 shares in the last quarter. 89.76% of the stock is owned by institutional investors and hedge funds.
Orthofix Medical Company Profile
(
Get Free Report)
Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company's core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.
Orthofix's product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
